"The NIH’s new 15% cap on indirect costs threatens U.S. biomedical research by reducing funds for vital infrastructure, labs, and compliance support.
Original Image Link
Source:idahobusinessreview.com
Original Image Link
Source:idahobusinessreview.com
Posted: 2025-02-12 07:47:00